NCT00002832View on ClinicalTrials.gov

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 1995

Primary Completion Date

March 31, 2002

Study Completion Date

March 31, 2002

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

Filgrastim

Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.

DRUG

Cyclosporine

IV daily on day -2, then orally once dose is tolerable, dose may be escalated.

DRUG

Decitabine

IV for 6 hours every 12 hr for 5 days.

PROCEDURE

Allogeneic Bone Marrow Transplantation

Stem cell infusion on Day 0.

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER